コンテンツへスキップ
Merck
すべての画像(1)

資料

安全性情報

PLA0302

Sigma-Aldrich

Goat anti-GAPDH Antibody, Affinity Purified

Powered by Bethyl Laboratories, Inc.

別名:

G3PD, GAPD, GAPDH, HEL-S-162eP, aging-associated gene 9 protein, epididymis secretory sperm binding protein Li 162eP, peptidyl-cysteine S-nitrosylase GAPDH

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

goat

品質水準

100

抗体製品の状態

affinity purified immunoglobulin

抗体製品タイプ

primary antibodies

グレード

Powered by Bethyl Laboratories, Inc.

化学種の反応性

human, mouse

濃度

1 mg/mL

テクニック

immunohistochemistry: 1:500-1:2,000
western blot: 1:500- 1:2,500

アクセッション番号

NP_002037.2

UniProtアクセッション番号

P04406

輸送温度

wet ice

保管温度

2-8°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

goat ... GAPDH(2597)

免疫原

The epitope recognized by PLA0302 maps to a region between residue 175 and 225 of human Glyceraldehyde-3-Phosphate Dehydrogenase using the numbering given in entry NP_002037.2 (GeneID 2597).

物理的形状

トリスクエン酸／リン酸塩緩衝液、pH 7～8、0.09％ アジ化ナトリウム含有

その他情報

In the process of carbohydrate metabolism, GAPDH (glyceraldehydes-3-phosphate dehydrogenase) catalyzes the oxidative phosphorylation of glyceraldehydes-3-phosphate to 1,3-diphosphoglycerate in the presence of nicotinamide adenine dinucleotide (NAD) and inorganic phosphate. In addition to its role in the oxidation of glucose, GAPDH has been shown to be involved in other cellular processes such as vesicle transport, DNA repair, DNA replication, cytoskeletal modulation, and tRNA export.

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our 製品選択ツール.

保管分類コード

12 - Non Combustible Liquids

WGK

nwg

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

PLA0302-100UL:
PLA0302-100UL-KC:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Xiaolei Lian et al.
Acta neuropathologica communications, 9(1), 88-88 (2021-05-19)
Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients each year in the United States. DIPG is noted for its lethality, as fewer than 1% of patients survive to five years. Multiple clinical trials
Lesya V Zelenchuk et al.
PloS one, 9(5), e97326-e97326 (2014-05-21)
PHEX or DMP1 mutations cause hypophosphatemic-rickets and altered energy metabolism. PHEX binds to DMP1-ASARM-motif to form a complex with α5β3 integrin that suppresses FGF23 expression. ASARM-peptides increase FGF23 by disrupting the PHEX-DMP1-Integrin complex. We used a 4.2 kDa peptide (SPR4)
Amane Araki et al.
Neurology, 82(20), 1813-1821 (2014-04-25)
The aim of this study was to clarify myocardial involvement and its clinical implications in subjects with spinal and bulbar muscular atrophy (SBMA), a neuromuscular disease affecting both neuronal and nonneuronal tissues. Two independent cardiologists evaluated ECGs from a total
Bo Cao et al.
Oncotarget, 5(6), 1646-1656 (2014-04-12)
Upregulation of constitutively-active androgen receptor splice variants (AR-Vs) has been implicated in AR-driven tumor progression in castration-resistant prostate cancer. To date, functional studies of AR-Vs have been focused mainly on their ability to regulate gene expression independent of the full-length
Paul Cottu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4314-4325 (2014-06-21)
Patients with luminal breast cancer (LBC) often become endocrine resistant over time. We investigated the molecular changes associated with acquired hormonoresistances in patient-derived xenografts of LBC. Two LBC xenografts (HBCx22 and HBCx34) were treated with different endocrine treatments (ET) to
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）